Yet, the selection of LC patients for a given treatment with KIs is limited to those with known driver mutations, that is, ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK, ROS and RET alterations.39 Here, KRAS is linked to laryngotracheoesophageal cleft.